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Objectives. Periodontitis is characterized by inﬂammatory destruction of periodontal tissue, loss of attachment, and bone resorption. The increase in reactive oxygen species (ROS) is responsible for the oxidative damage occurring in periodontal tissues.
Melatonin has important immunomodulatory, anti-inﬂammatory, and powerful antioxidant functions. The current study was
carried out to evaluate the eﬀect of topical melatonin gel as an adjunct to nonsurgical periodontal therapy. Methods. This splitmouth randomized controlled clinical trial was performed on 24 patients with grade II periodontitis. Two sites in each patient
were randomly assigned; test sites were treated by nonsurgical therapy followed by intrapocket application of 5% melatonin gel.
Control sites were treated by nonsurgical therapy followed by intrapocket application of placebo gel. Both the melatonin and
placebo gel were applied weekly once for four weeks. Assessment of clinical parameters (PD and CAL) was done at baseline and 3
months after therapy. Total antioxidative capacity (TAC) and matrix metalloproteinase-9 (MMP-9) levels in GCF were also
evaluated utilizing commercially available enzyme-linked immunosorbent assay kits (ELISA) at baseline and 3 months after
therapy. Results. Treatment with topical melatonin was associated with a reduction in periodontal inﬂammation reﬂected as an
improvement in the clinical periodontal parameters. Melatonin-treated sites showed a more statistically signiﬁcant percent
reduction in PD and more statistically signiﬁcant percent gain in CAL than the control site. Additionally, a signiﬁcant increase in
TAC and a signiﬁcant decrease in MMP-9 levels in GCF were found in melatonin-treated sites in comparison to control sites.
Conclusions. The adjunctive use of topical melatonin gel with nonsurgical periodontal therapy has potent anti-inﬂammatory and
antioxidant activity in the treatment of grade II periodontitis patients.

1. Background
Periodontal disease is an oral inﬂammatory process that is
typically initiated by bacterial infection stimulating the host
response to produce various inﬂammatory mediators in high
levels, which are also involved in the initiation and progression of periodontal disease [1]. Such mediators generate
a cascade reaction that eventually leads to the irreversible
degradation of connective tissues and bone, with subsequent
loss of periodontal attachment [2].
Periodontal tissue inﬁltration by polymorphonuclear
leukocytes (PMNs) and macrophages and consequent

phagocytosis features a burst of O2 consumption producing
higher concentrations of reactive oxygen species (ROS) that
exerts a cytotoxic eﬀect on periodontal tissues [3]. Various
studies have demonstrated that oxidative stress induced by
PMNs can be the primary etiology for the damage of
periodontal tissue in periodontal disease [4]. It is worth
highlighting that patients with periodontitis have often
revealed higher levels of biomarkers indicating ROS-induced tissue damage than that observed in matched controls
[5].
Matrix metalloproteinases (MMPs) are crucial proteases
involved in periodontal tissue destruction. MMP-9 is a type
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IV collagenase that originates from PMNs, ﬁbroblasts,
macrophages, epithelial cells, and pathogenic bacteria [6]. It
is one of the main proteases engaged in destructive periodontal disease and controls a number of functions related
to inﬂammation. MMP-9 levels are heightened during
periodontal inﬂammation [7].
Melatonin is a natural compound produced by the pineal
gland, bone marrow, retina, and the immune system with a
primary function of regulating the circadian rhythm [8]. It
also plays an anti-inﬂammatory, immunomodulatory, and
antioncotic role. Melatonin inhibits invasion, endometriosis,
and ﬁbrosis whilst boosting embryogenesis and wound
healing by regulating the expression of ROS, MMPs, and
growth factors [9].
Melatonin has been studied extensively and has shown
to reduce oxidative stress through several diﬀerent
mechanisms. On the one hand, melatonin acts as an active
scavenger of exogenous and endogenous ROS. On the
other hand, melatonin also stimulates some vital antioxidant enzymes, namely, superoxide dismutase, glutathione reductase, glutathione peroxidase, and vitamin C
[10].
Of particular importance, melatonin was found to
inﬂuence bone regeneration and ﬁbroblast activation by
stimulating osteoblast diﬀerentiation and bone formation.
Moreover, melatonin promotes type I collagen ﬁbers
synthesis [11]. Additionally, melatonin treatment was
reported to stimulate osteoblast proliferation, diﬀerentiation, and activation while inhibiting bone resorption
[11].
In addition to the downregulatory eﬀect of melatonin on
the expression of proinﬂammatory mediators such as interleukin-6, prostaglandins, C-reactive protein, and tumor
necrosis factor-alpha, it also downregulates the receptor
activator of nuclear factor kappa beta ligand (RANKL)/
osteoprotegerin (OPG) ratios to decrease periodontal inﬂammation [12].
Several studies were conducted evaluating the melatonin
eﬀect on periodontal disease but as oral supplementation or
in the topical forms other than the gel form used in the
present study. Melatonin treatment has been described to
decrease periodontitis in diabetic rats [13]. Moreover, topical
melatonin application in patients with diabetes was related
to a decrease in salivary RANKL concentrations and rise in
salivary OPG concentrations, indicating that melatonin has
the potential of reducing bone loss, improving bone quality,
and hindering the progression of periodontal destruction
[12, 14, 15]. Furthermore, local melatonin administration in
rats produced a signiﬁcant reduction of bone resorption
[16]. According to the mentioned studies, it can be postulated that combining topical administration of melatonin
with conventional periodontal therapy could enhance the
treatment outcomes [17].
Consequently, the current study was designed to evaluate the eﬀect of topical melatonin gel as an adjunct to
nonsurgical therapy versus nonsurgical therapy alone on the
clinical parameters (PI, GI, PD, and CAL) as well as total
antioxidative capacity (TAC) and MMP-9 in GCF of stage II
periodontitis patient.
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2. Study Population and Methodology
2.1. Study Design. This split-mouth randomized controlled
clinical trial was carried out in Periodontology clinic, Faculty
of Dentistry, Cairo University.
2.2. Patients’ Selection. This study was conducted on a total
of 30 patients (6 patients did not show up at follow-up)
ending in 24 patients (17 females and 7 males with age range
32–55) having stage II periodontitis. Patients were recruited
from the Periodontology Clinic, Faculty of Dentistry, Cairo
University, and informed about the follow-up visits needed
(Figure 1). They also instructed to avoid any medication that
may interfere with the trial during the study.
The aim of the current study was to evaluate the eﬀect of
topical melatonin gel as an adjunct to nonsurgical periodontal therapy on the clinical parameters (pocket depth,
PD; clinical attachment loss, CAL; plaque index, PI; and
gingival index, GI) as well as TAC and MMP-9 level in GCF
of stage II periodontitis patient. Total sample size of 24
patients was suﬃcient to detect the medium eﬀect size
(f � 0.3) estimated by Cutando et al. with power 85% and 5%
signiﬁcance level [18]. This number had to be increased to 30
patients to overcome losses during follow-up done by G
power.
2.3. Eligibility Criteria. Patients eligible for the trial must be
complied with all the following: patients were selected to be
systemically free according to the modiﬁed Cornell Medical
Index. Patients with stage II periodontitis was diagnosed as
having interdental CAL is detectable at ≥2 nonadjacent
teeth, or buccal or oral CAL ≥3 mm with pocketing >3 mm is
detectable at ≥2 teeth and CAL 3-4 mm and maximum
probing depth ≤5 mm [19]. Exclusion criteria include
smokers, pregnant and lactating females, patients received
any type of periodontal treatment in the past 6 months prior
to examination, patients who used antibiotic or anti-inﬂammatory drugs or antioxidants within the 6 months
preceding the beginning of the study, and patients working
in night shifts or received any drug that known to alter
melatonin levels (e.g., for sleeping disorders).

3. Ethical Procedures
Each patient was informed about the detailed procedure, the
side eﬀects of biopsy taking, and follow-up appointments, if
needed. Each subject signed an informed written consent
form. The patients consent to photography, charting, as well
as radiographic examination to be performed, provided that
their identity is not revealed and understood why it was
necessary to accomplish these procedures. The Research
Ethics Committee of Faculty of Dentistry, Cairo University,
revised and approved this research on 24/12/2017 with the
number (17-12-27).
3.1. Preoperative Evaluation. Patients eligible for the study
were screened by a comprehensive periodontal examination,
and full periodontal charts were obtained. Periapical
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Patients recruitment
n = 40

Inclusion criteria
Grade II periodontitis
systemically healthy
n = 36

Exclusion criteria
Lack of compliance with oral hygiene
n = 30
Randomization

Test sites

Control sites

Subgingival enlargement + locally
applied melatonin gel
N = 30

Subgingival enlargement + locally
applied melatonin gel
N = 30

Drop out

6 patients lost to follow-up

Test sites

Test sites

Subgingival enlargement + locally
applied melatonin gel
N = 24

Subgingival enlargement + locally
applied melatonin gel
N = 24

Figure 1: Flowchart of the study.

radiographs were taken for periodontitis patients, at sites of
attachment loss for diagnosis of the case.
After proper examination and diagnosis, full mouth
supra- and subgingival scaling and root planning were
performed in all patients over 2 weeks using scalers and
Gracey Curettes from Hu-Friedy, and all patients received
an oral hygiene instruction.

3.2.1. Melatonin Oral Gel Preparation. Pure melatonin was
purchased from Bulk Supplements (USA) Company and
prepared as an oral gel 5% by El Ezaby Pharmacy. The used
base was 1% carboxymethyl cellulose in distilled water. The
placebo gel was also prepared by El Ezaby Pharmacy and
consisted of 1% carboxymethyl cellulose in distilled water
alone.

3.2. Intervention. Two sites in each patient were randomly
assigned using random allocation computer software to
receive one of the following treatment modalities as follows:
the test site was treated by nonsurgical therapy followed by
intrapocket application of 5% melatonin gel using a plastic
disposable syringe with plastic ﬂexible tip preloaded to
deliver the melatonin inside the pocket. The control site was
treated by nonsurgical therapy followed by intrapocket
application of placebo gel using a plastic disposable syringe
with plastic ﬂexible tip (manufactured by SUNG SHIM
Medical CO., LTD, made in Korea insulin syringe, 1 ml with
gauge 29G). Both the melatonin and placebo gel were applied weekly once for four weeks.

3.3. Allocation. The sequence was generated through
computer-generated random numbers with an allocation
ratio of 1 : 1. The melatonin and placebo gels were identical
in appearance and were placed in prepacked identical syringes (those used for insulin injection) which were numbered for each patient according to the randomization
schedule. Sequentially numbered containers for concealment were done by the coinvestigator.

4. Implementation
The main investigator was responsible for the enrollment of
participants, assigning participants to interventions, and
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performing treatment. The coinvestigators were responsible
for generating the allocation sequence. The main investigator was responsible for the assessment of outcomes.
4.1. Blinding. The current study was triple blinded. Blinding
was performed to the patients, the evaluator of outcomes,
and the statistician.
4.2. Strategies to Improve Adherence to Intervention Protocol.
Printed follow-up schedule cards with reminder calls or
messages were utilized to improve adherence.

5. Outcomes
5.1. Clinical Parameters. The following clinical parameters
were assessed by the main investigator at baseline and 3
months after periodontal treatment:
(1) Plaque Index: the amount of dental plaque was
assessed by the Plaque Index in order to monitor oral
hygiene performance by the patient [20].
(2) Gingival Index (GI): the gingival status was evaluated
using the Gingival Index to evaluate the presence or
absence of gingival inﬂammation [21].
(3) Probing pocket depth (PD): the distance between the
gingival margin and the deepest part of the pocket
was measured using William’s graduated periodontal probe.
(4) Clinical attachment level (CAL): clinical attachment
loss was measured from the cemento-enamel junction to the deepest part of the pocket using William’s
graduated periodontal probe.
5.2. Biochemical Analysis. Evaluation of changes in the GCF
level of TAC and MMP-9 was done using enzyme-linked
immunosorbent assay (ELISA). The unit of measurement is
micromole (μmol/L) in case of TAC and picogram (pg/µl) in
case of MMP-9.

6. Collection of Gingival Crevicular Fluid
(GCF) Samples
The GCF samples were collected from the sites with the
deepest PD and radiographic evidence of bone loss. The
sample was collected at baseline and 3 months following
periodontal treatment. The GCF samples were obtained as
follows: after proper isolation of the sample site with cotton
rolls (to prevent contamination with saliva), the tooth was
air-dried, and a sterile ﬁlter paper strip (1.5 × 20 mm) was
inserted into the sulci/pockets until minimal resistance was
felt and left in the place for 1 minute. Strips contaminated by
blood or saliva were excluded. After GCF collection, the
strips were placed immediately in sterile Eppendorf tubes.
The tubes were stored in liquid nitrogen (−80°C) until
biochemical analysis [22].

7. Determination of TAC in GCF
The determination of the antioxidative capacity was performed using a kit provided by Immundiagnostik, Germany,
by the reaction of antioxidants in the sample with a deﬁned
amount of exogenously provided (H2O2), and the antioxidants in the sample eliminated a certain amount of the
provided hydrogen peroxide. The residual H2O2 was determined photometrically by an enzymatic reaction which
involved the conversion of tetramethylbenzidine (TMB) to a
colored product. After addition of a stop solution, the
samples were measured at 450 nm in a microtiter plate
reader. The quantiﬁcation was performed by the delivered
calibrator.

8. Determination of MMP-9 in GCF
Determination of MMP-9 levels in GCF was done using
human MMP-9 ELISA kit produced by Aﬀymetrix eBioscience. This assay is a quantitative sandwich enzyme immunoassay technique. A monoclonal antibody speciﬁc for
MMP-9 has been precoated onto a microplate. Samples were
poured into the wells, and any MMP-9 present was conjugated with the immobilized antibody. The unconjugated
remnants were removed by washing. The enzyme-linked
monoclonal antibody speciﬁc for MMP-9 was added to all
wells. A substrate solution was inserted into the wells after
washing to remove any unconjugated antibody-enzyme
reagent. Color appeared in proportion to the amount of
MMP-9 conjugated in the ﬁrst step. The color development
was stopped, and the intensity of the color was measured by
ELISA reader.

9. Statistical Analysis
Kolmogorov–Smirnov and Shapiro–Wilk tests were used to
check if numerical data had a normal distribution or not.
PD, CAL, TAC, and MMP-9 data showed parametric distribution while GI and PI data showed nonparametric
distribution. Numerical data were presented as mean, median, standard deviation (SD), minimum, maximum, and
95% conﬁdence interval (95% CI) values. For parametric
data, a paired t-test was used to compare between test and
control sites as well as to study the changes after treatment.
For nonparametric data, the Wilcoxon signed-rank test
was used to compare between test and control sites as well as
to study the changes after treatment. The Kruskal–Wallis test
was used to compare between TAC and MMP-9 levels of the
two sites. Mann–Whitney U test with Bonferroni’s adjustment was used for pairwise comparisons when the Kruskal–Wallis test is signiﬁcant. The signiﬁcance level was set at
P ≤ 0.05. Statistical analysis was performed with IBM
SPSS Statistics Version 20 for Windows.

®

®

10. Results
The present study included a total of 30 patients (6 patients
did not show up at follow-up) ending in 24 patients (12
females and 10 males with age range 32–55) having stage II
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periodontitis. In each of the 24 patients, two sites were
randomly assigned to receive one of the intervention protocols (nonsurgical therapy and topical application of
melatonin gel versus nonsurgical therapy and topical application of placebo gel). No adverse eﬀects were reported by
the patients who received 5% of melatonin oral gel or
placebo gel.
10.1. Clinical Parameters. The results of the clinical parameters at baseline and 3 months after treatment are shown
in Tables 1 and 2. Regarding PI, both sites (test and control)
showed statistically signiﬁcant reduction in plaque scores 3
months after treatment. At the end of the follow-up period,
there was no statistically signiﬁcant diﬀerence between mean
PI in both sites. The result applying to GI in both sites
showed a statistically signiﬁcant reduction in GI scores 3
months after treatment, whereas there was no statistically
signiﬁcant diﬀerence between both sites at the end of the
study.
Regarding PD and CAL, both sites showed statistically
signiﬁcant reduction in PD and gain in CAL 3 months after
treatment; however, test site showed more statistically signiﬁcant percent reduction in PD and more statistically
signiﬁcant percent gain in CAL than the control site.
10.2. Biochemical Analysis
10.2.1. Total Antioxidant Capacity (TAC%). At the test site,
mean ± SD of TAC at baseline was 284.5 ± 33.2 (μmol/L) that
increased to 584.4 ± 64.1 (μmol/L) after treatment. Mean
diﬀerence at baseline and 3 months after treatment was 299.9
with a 95% conﬁdence interval (CI) (254.6–345.1). This
diﬀerence was statistically signiﬁcant (P < 0.001).
At the control site, mean ± SD of TAC at baseline was
283.2 ± 30.9 (μmol/L) that increased to 437.3 ± 60.4 (μmol/L)
3 months posttreatment. Mean diﬀerence at baseline and
after three months was 154.1 with 95% CI (114.4–193.8). This
diﬀerence was statistically signiﬁcant (P < 0.001).
Although both sites showed a statistically signiﬁcant
increase in TAC, the test site showed a more statistically
signiﬁcant % increase in TAC (109.21 ± 41.79%) than the
control site with a % increase in TAC (56.25 ± 27.64%) with
P < 0.001 (Figure 2).

10.2.2. Matrix Metalloproteinase-9. At the test site,
mean ± SD of MMP-9 at baseline was 77.71 ± 2.86 (pg/µL)
that decreased to 31.20 ± 2.3 (pg/µL) 3 months after treatment. There was a statistically signiﬁcant reduction in the
MMP-9 level with P < 0.001. At control site, mean ± SD of
MMP-9 at baseline was 77.53 ± 3.4 (pg/µL) and then decreased to 47.1 ± 1.8 (pg/µL) 3 months after treatment. There
was a statistically signiﬁcant reduction in the MMP-9 level
with P < 0.001.
Although both sites showed a statistically signiﬁcant
reduction in MMP-9, test site showed more statistically
signiﬁcant % reduction in MMP-9 (−59.57 ± 14.42%) than
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the control site with % reduction in MMP-9 of
−39.25 ± 16.46% with P < 0.001 (Figure 3).

11. Discussion
Periodontal disease is characterized by inﬂammation-induced damage of periodontal tissue, loss of attachment, and
alveolar bone loss. It is well understood that the increase in
ROS produced by PMNs or other cells such as ﬁbroblasts in
periodontal disease stands behind the oxidative damage
occurring in periodontal tissues which could be also associated with a reduction in the antioxidant defense mechanism [23]. When endogenous antioxidants are unable to
lessen the damaging eﬀects of ROS eﬃciently, tissue damage
can result. The host capability to scavenge ROS is considered
as a vital defensive mechanism to counteract the ROS-related periodontal tissue damage [5].
Melatonin is a pleiotropic multitasking molecule; among
its versatile functions, it has an immunomodulatory and
anti-inﬂammatory eﬀects, and it is a remarkable free radical
scavenger at the same time [24]; such functions are of
paramount signiﬁcance from a periodontal perspective as
per augmenting the host defense and restoring the balance
between the antioxidant and the pro-oxidant systems, thus
reducing the oxidative damage and destruction of periodontal tissue. The present study was hence planned to
estimate the eﬀect of locally delivered melatonin gel as an
adjunct to nonsurgical periodontal therapy on the clinical
parameters (PD, CAL, PI, and GI) as well as TAC and MMP9 levels in GCF of stage II periodontitis patient. In the
present study, melatonin was applied in a gel form inside the
pocket to increase the bioadhesion properties of the material
and thus prolong its biological eﬀects.
Results of the present study emphasize the favorable
beneﬁts of the local delivery of melatonin gel on periodontal
disease reﬂected by the favorable eﬀects obtained concerning
the clinical parameters including PI, GI, PD, and CAL.
Comparisons in all parameters pre and posttreatment with
melatonin yielded statistically signiﬁcant results. Moreover,
melatonin-treated sites showed more statistically signiﬁcant
percent reduction in PD and more statistically signiﬁcant
percent gain in CAL than the control site. These results are in
accordance with the study of Montero et al. [24] that reported that the topical application of melatonin has a
number of positive eﬀects on periodontal health, and it
resulted in signiﬁcant improvement of clinical parameters as
the Gingival Index and pocket depth and also reported
improved bone formation and osteoblast diﬀerentiation
subsequent to topical application of melatonin.
An adequate balance between the host tissue production
of ROS and TAC plays a vital role in periodontal tissue
homeostasis leading to the prevention of tissue destruction
upon immune system stimulation by periodontal pathogenic
challenge [25]. The potent antioxidant eﬀect of melatonin
was conﬁrmed in our study as per the statistically signiﬁcant
increase in TAC that was evident 3 months after starting the
local delivery of melatonin. Moreover, test sites showed a
more statistically signiﬁcant percent increase in TAC than
the control site.
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Table 1: Mean and standard deviation values for inter- and intragroup comparisons in all clinical variables between test and control sites.
Test site (melatonin gel), n � 24

Control site (placebo gel), n � 24

P value

2 ± 0.7
0.7 ± 0.6
<0.0001∗

1.96 ± 0.6
0.7 ± 0.6
<0.0001∗

0.83
0.83

2.5 ± 0.5
0.6 ± 0.5
<0.001∗

2.4 ± 0.5
0.7 ± 0.5
<0.001∗

0.5
0.5

4.3 ± 0.8
2.9 ± 0.7
<0.001∗

4.0 ± 0.6
3.1 ± 0.7
<0.001∗

0.1485
0.3275

4.7 ± 0.9
3.5 ± 0.6
<0.001∗

4.3 ± 0.6
3.7 ± 0.6
<0.001∗

0.07
0.254

Plaque Index (PI)
Baseline
Posttreatment
P value
Gingival Index (GI)
Baseline
Posttreatment
P value
Probing depth (PD)
Baseline
Posttreatment
P value
Clinical attachment level (CAL)
Baseline
Posttreatment
P value

Table 2: Mean and standard deviation values for comparing % changes in all clinical variables among test and control sites.
Clinical parameters
Plaque Index (PI)
Baseline
Posttreatment
% change
Gingival Index (GI)
Baseline
Posttreatment
% change
Probing depth (PD)
Baseline
Posttreatment
% change
Clinical attachment level (CAL)
Baseline
Posttreatment
% change

Test site (melatonin gel), n � 24

Control site (placebo gel), n � 24

P value

2 ± 0.7
0.7 ± 0.6
−65%

1.96 ± 0.6
0.7 ± 0.6
−64.29%

0.83
0.83
<0.001∗

2.5 ± 0.5
0.6 ± 0.5
−80%

2.4 ± 0.5
0.7 ± 0.5
−70.83%

0.5
0.5
<0.001∗

4.3 ± 0.8
2.9 ± 0.7
−32.56%

4.0 ± 0.6
3.1 ± 0.7
−22.5%

0.1485
0.3275
<0.001∗

4.7 ± 0.9
3.5 ± 0.6
−25.53%

4.3 ± 0.6
3.7 ± 0.6
−13.95%

0.07
0.254
<0.001∗

120

0

100

Melatonin sites

Control sites

–10

80
–20

109.21

60

–30
40
56.25

20

–50
0
TAC
Melatonin sites
Control sites

Figure 2: Bar chart of TAC percent change in both sites.

This was in line with previous studies which observed
that the considerable oxidative stress in periodontitis

–39.25

–40
–59.57

–60
–70

Figure 3: Bar chart of MMP-9 percent change in both sites.

patients was signiﬁcantly reduced by melatonin administration and declared that not only melatonin but also several
endogenously generated metabolites of melatonin function
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as free radical scavenger [5]. Similarly, melatonin application
was reported to protect the periodontal tissues against ROS
injury resulting from inﬂammatory reactions by reducing
the elevated oxidative stress levels in these patients and that
it may reduce alveolar bone loss [26]. Moreover, melatonin
supplementation adjunctive to nonsurgical periodontal
therapy signiﬁcantly increased the serum levels of TAC
compared with the baseline [27].
Degradation of collagen ﬁbers occurring in periodontal
disease is a vital step in periodontal attachment loss. This
degradation is achieved by MMPs released by the resident
periodontal cells in response to the inﬂammatory stimuli.
MMP-9 belongs to the collagenases family and is known to
contribute signiﬁcantly to connective tissue destruction [28].
MMP-9 levels were reported to be increased during periodontal inﬂammation [7]. And a signiﬁcant decline in
MMP-9 levels following periodontal therapy has also been
observed [6].
In this study, combining locally delivered melatonin with
nonsurgical periodontal therapy resulted in a signiﬁcant
decrease in GCF MMP-9 levels and showed more signiﬁcant
percent reduction in MMP-9 than the control site. To the best
of our knowledge, this is the ﬁrst study to assess the eﬀect of
locally delivered melatonin on GCF MMP-9 levels in periodontitis and so it is diﬃcult to exactly correlate our results.
However, the eﬀect of melatonin on MMP-9 was investigated
in association with other diseases and conditions where
melatonin was reported to cause signiﬁcant inhibition of the
MMP-9 activity in both a dose- and time-dependent manner
[29]. Additionally, melatonin was found to suppress MMP-9
expression at the protein and mRNA levels and to inhibit the
enzymatic activity of MMP-9 [30]. The inhibition of the
MMP-9 activity by melatonin was suggested to be due to the
suppression of TNF-α release by melatonin [9].

12. Conclusion
The ﬁndings of the present study revealed a signiﬁcant increase in TAC after intrapocket application of melatonin gel
reﬂecting its powerful antioxidant potential together with a
signiﬁcant reduction of MMP-9, the marker of connective
tissue degradation. With the above background, it can be
concluded that the adjunctive eﬀects of locally delivered
melatonin gel with nonsurgical periodontal therapy have a
positive eﬀect on inﬂammatory and antioxidant parameters
in periodontitis patients conferring a new aspect to the
management of periodontitis. Thus, melatonin with the
validated immunomodulatory, anti-inﬂammatory, and
powerful antioxidant functions can be considered as a novel
addition to the standard of care procedures for periodontal
therapy to enhance treatment outcome.

Abbreviations
PMNs:
ROS:
MMPs:
RANKL:

Polymorphonuclear leukocytes
Reactive oxygen species
Matrix metalloproteinases
Receptor activator of nuclear factor kappa beta
ligand
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OPG:
PI:
GI:
PD:
CAL:
TAC:
GCF:
H2O2:
TMB:
ELISA:
SD:

Osteoprotegerin
Plaque Index
Gingival Index
Probing depth
Clinical attachment level
Total antioxidative capacity
Gingival crevicular ﬂuid
Hydrogen peroxide
Tetramethylbenzidine
Enzyme-linked immunosorbent assay
Standard deviation.

Data Availability
The data that support the ﬁndings of this study are available
from faulty of Dentistry, Cairo University, but restrictions
apply to the availability of these data, which were used under
license for the current study and so are not publicly available.
Data are however available from the authors upon reasonable request and with permission of faculty of Dentistry,
Cairo University.

Additional Points
Clinical relevance is as follows:
(i) Scientiﬁc rationale: melatonin has a validated immunomodulatory and powerful antioxidant function. Its usage was considered as a novel addition to
the standard of care procedures for periodontal
therapy. The current study was conducted to evaluate the eﬀect of topical melatonin gel as an adjunct
to nonsurgical periodontal therapy.
(ii) Principal ﬁndings: the local application of melatonin resulted in statistical signiﬁcant reduction of
probing depth and MMP-9 levels, while statistical
signiﬁcant increases the attachment level as well as
total antioxidant capacity.
(iii) Practical implications: the intrapocket local application of melatonin is highly recommended as an
adjunctive to nonsurgical periodontal therapy.
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[23] M. Özdem, “Melatonin: it’s antioxidant eﬀects on periodontal
disease,” Journal of Healthcare Communications, vol. 3, no. 1,
p. 17, 2018.
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